Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Financial Year ended March 31, 2026

Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI Listing Regulations

Audit Opinion:

Unmodified opinion on both standalone and consolidated financial results for FY26 from statutory auditor M/s C.H. Padliya & Co.

Auditor’s Comment:

No qualifications or modifications noted in audit reports. Auditors confirmed financial results present true and fair view in accordance with Ind AS.

Key Financial Highlights [Rs. in Lakhs except EPS]:

Standalone Results:

Quarter Ended March 31, 2026:

  • Revenue from Operations: ₹3,139.56 (vs ₹3,911.20 in Q4 FY25, -19.7% YoY)
  • Total Income: ₹3,121.18
  • Net Profit: ₹135.70 (vs ₹(194.81) loss in Q4 FY25)
  • EPS: ₹0.64

Financial Year Ended March 31, 2026:

  • Revenue from Operations: ₹10,580.96 (vs ₹11,164.49 in FY25, -5.2% YoY)
  • Total Income: ₹12,153.07
  • Net Profit: ₹1,495.31 (vs ₹1,967.94 in FY25, -24.0% YoY)
  • EPS: ₹7.10
  • Other Equity: ₹17,990.33
  • Cash and Cash Equivalents: ₹261.14
  • Debt: Not specified

Consolidated Results:

Quarter Ended March 31, 2026:

  • Revenue from Operations: ₹3,139.56
  • Total Income: ₹3,123.70
  • Net Profit: ₹138.26
  • EPS: ₹0.24

Financial Year Ended March 31, 2026:

  • Revenue from Operations: ₹10,580.96 (vs ₹11,245.19 in FY25, -5.9% YoY)
  • Total Income: ₹12,156.64
  • Net Profit: ₹1,500.98 (vs ₹950.31 in FY25, +57.9% YoY)
  • EPS: ₹7.13
  • Other Equity: ₹16,524.03
  • Cash and Cash Equivalents: ₹423.87
  • Debt: Not specified

Segment-wise Performance:

The company operates in a single segment of Drugs & Chemicals.

Corporate Actions:

  • No dividend declarations, share splits, bonus issues, or buybacks announced
  • No capital raising activities announced

Other Significant Information:

  • Other income for the quarter includes unrealized profit from increase in fair market value of investments
  • The financial results for Q4 FY26 represent balancing figures between audited full-year figures and previously published unaudited YTD figures
  • Subsidiary included in consolidation: Norfolk Mercantile Private Limited
  • No exceptional items reported in either standalone or consolidated results
  • No change in accounting policy affecting comparability
  • No forward-looking guidance or management outlook provided

Balance Sheet Highlights [As of March 31, 2026, Rs. in Lakhs]:

Standalone:

  • Total Assets: ₹25,137.90
  • Equity Share Capital: ₹2,104.06
  • Other Equity: ₹17,553.92
  • Inventories: ₹1,333.28
  • Trade Receivables: ₹4,083.07
  • Cash and Cash Equivalents: ₹261.14

Consolidated:

  • Total Assets: ₹24,214.47
  • Equity Share Capital: ₹2,104.06
  • Other Equity: ₹16,524.03
  • Inventories: ₹1,333.28
  • Trade Receivables: ₹4,083.07
  • Cash and Cash Equivalents: ₹423.87

Cash Flow Highlights [FY26, Rs. in Lakhs]:

Standalone:

  • Net Cash Flow from Operating Activities: ₹995.04
  • Net Cash Flow from Investing Activities: ₹(1,158.08)
  • Net Cash Flow from Financing Activities: ₹115.82
  • Net Increase/(Decrease) in Cash: ₹(47.22)

Consolidated:

  • Net Cash Flow from Operating Activities: ₹995.04
  • Net Cash Flow from Investing Activities: ₹(1,155.63)
  • Net Cash Flow from Financing Activities: ₹222.21
  • Net Increase/(Decrease) in Cash: ₹61.62